References
- Cavaletti G, Bogliun G, Marzorati L, Tredici G, Colombo N, Parma G, et al. Long-term peripheral neurotoxicity of cisplatin in patients with successfully treated epithelial ovarian cancer. Anticancer Res 1994; 14: 1287–1292
- Giannini F, Volpi N, Rossi S, Passero S, Fimiani M, Cerase A. Thalidomide-induced neuropathy: a ganglionopathy?. Neurology 2003; 60: 877–878
- Chaudhry V, Cornblath D R, Corse A, Freimer M, Simmons-O'Brien E, Vogelsang G. Thalidomide-induced neuropathy. Neurology 2002; 59: 1872–1875
- Apfel S C, Zochodne D W. Thalidomide neuropathy: too much or too long?. Neurology 2004; 62: 2158–2159
- Umapathi T, Chaudhry V. Toxic neuropathy. Curr Opin Neurol 2005; 18: 574–580
- Aronson I K, Yu R, West D P, van den Broek H, Antel J. Thalidomide-induced peripheral neuropathy. Effect of serum factor on nerve cultures. Arch Dermatol 1984; 120: 1466–1470
- Fullerton P M, O'Sullivan D J. Thalidomide neuropathy: a clinical electrophysiological, and histological follow-up study. J Neurol Neurosurg Psychiatry 1968; 31: 543–551
- Mileshkin L, Stark R, Day B, Seymour J F, Zeldis J B, Prince H M. Development of neuropathy in patients with myeloma treated with thalidomide – patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006; 24: 4507–4514
- Offidani M, Corvatta L, Marconi M, Malerba L, Mele A, Olivieri A, et al. Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. Eur J Haematol 2004; 72: 403–409
- Tosi P, Zamagni E, Cellini C, Plasmati R, Cangini D, Tacchetti P, et al. Neurological toxicity of long-term (>1 year) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 2005; 74: 212–216
- Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006; 132: 584–593
- Rajkumar S V. Thalidomide in newly diagnosed multiple myeloma and overview of experience in smoldering/indolent disease. Semin Hematol 2003; 40: 17–22
- Rajkumar S V, Blood E, Vesole D, Fonseca R, Greipp P R. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006; 24: 431–436
- Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021–1030
- Palumbo A, Bringhen S, Caravita T, Merla E, Capparella V, Callea V, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006; 367: 825–831
- Molloy F M, Floeter M K, Syed N A, Sandbrink F, Culcea E, Steinberg S M, et al. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve 2001; 24: 1050–1057
- Yellen S B, Cella D F, Leslie W T. Age and clinical decision making in oncology patients. J Natl Cancer Inst 1994; 86: 1766–1770
- Mileshkin L, Biagi J J, Mitchell P, Underhill C, Grigg A, Bell R, et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003; 102: 69–77
- Baz R, Alemany C, Green R, Hussein M A. Prevalence of vitamin B12 deficiency in patients with plasma cell dyscrasias: a retrospective review. Cancer 2004; 101: 790–795
- Pathak R D, Jayaraj K, Blonde L. Thalidomide-associated hyperglycemia and diabetes: case report and review of literature. Diabetes Care 2003; 26: 1322–1323
- Cavaletti G, Beronio A, Reni L, Ghiglione E, Schenone A, Briani C, et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology 2004; 62: 2291–2293
- Cherian G, Thomas D W, Rule S AJ. The efficacy of low dose thalidomide in refractory/relapsed myeloma – a retrospective audit. Leuk Lymphoma 2006; 47(11)2409–2411
- Wechalekar A D, Chen C I, Sutton D, Reece D, Voralia M, Stewart A K. Intermediate dose thalidomide (200 mg daily) has comparable efficacy and less toxicity than higher doses in relapsed multiple myeloma. Leuk Lymphoma 2003; 44: 1147–1149
- Durie B G. Low-dose thalidomide in myeloma: efficacy and biologic significance. Semin Oncol 2002; 29: 34–38
- Kees M, Dimou G, Sillaber C, Drach J, Ackermann J, Lechner K, et al. Low dose thalidomide in patients with relapsed or refractory multiple myeloma. Leuk Lymphoma 2003; 44: 1943–1946